ReviewFrontiers in pediatrics2025
Current methods in the diagnosis of invasive meningococcal disease.
Review in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Meningococcal vaccination counts and public attention: A time-series study from Türkiye.Human vaccines & immunotherapeutics · 2026Article
- Pediatric invasive meningococcal disease in Türkiye during the post-pandemic period: increased reported cases and predominance of serogroup B and severity determined by a clinical form in a multicenter hospital-based cohort.European journal of pediatrics · 2026Article
- Burden of Invasive Meningococcal Disease: Evolving Epidemiology and Implications for Prevention Policy.Infectious diseases and therapy · 2026Review
- Meningococcal serogroup W ST-11 causing meningitis, endogenous endophthalmitis, and septic arthritis in a child.BMC pediatrics · 2026Article
- Graph-based and molecular modeling approaches to identify TpiA as a noval therapeutic target in Neisseria meningitidis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Meningococcal Disease in Older Adults: Challenges in Diagnosis and Management.Infectious diseases and therapy · 2026Review
- Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive meningococcal disease (IMD) remains a significant health concern due to its global distribution, potential for epidemic spread, unpredictable nature, rapid progression, and high mortality rates or permanent sequelae. The global elimination of meningococcal illness
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.